: In diabetes, pancreatic beta cell mass declines significantly prior
Introduction
In both Type 1 and Type 2 diabetes, the ability of the beta cells in the pancreatic islets of Langerhans to produce insulin is disrupted.
There is an extensive preclinical period of time during which beta cell mass is significantly reduced prior to the onset of fasting hyperglycemia 1 , and therefore, there have been several efforts to detect these changes non-invasively, with the hypothesis that disease onset may be delayed and/or halted. Such efforts have focused on engineering transgenic mice in which uptake of an imaging contrast agent is genetically enhanced in beta cells using the mouse insulin promoter 2 or on identifying biomarkers on the beta cell membrane that can be targeted by specific ligands that carry image contrast 3, 4 .
We 5 and others 6,7 have developed transgenic mouse models in which changes in beta cell mass can be imaged by positron emission tomography (PET) or bioluminescence. While using bioluminescence to image these same changes in beta cell mass is a more sensitive and cost-effective approach 8 , PET has the advantage of being a clinical imaging modality, and our study showed that PET had the sensitivity to track changes in beta cell mass before the onset of fasting hyperglycemia in the context of a reporter gene. For a more clinically applicable approach, PET probes that target the vesicular monoamine transporter (VMAT2) 3, 9 and the glucagon-like peptide-1 receptor (GLP-1R) on the surface of the beta cell 10,11 are available. While VMAT2 targeting had some initial success in humans, there appears to be heterogenous VMAT2 expression among beta cell population, thus limiting its use in detecting changes in beta cell mass 12 . Targeting the GLP-1R using peptide analogs of GLP-1 and exendin-4 have been shown to be useful in imaging benign insulinomas and transplanted islets 10, 13, 14 , but have very limited capacity to image beta cells in the native rodent pancreas 15, 16 . This is due largely to unfavourable pharmacokinetics that result in accumulation of PET signal in the kidneys and liver 17 , thus obscuring any signal that might have been emitted from pancreatic beta cells.
Although targeting these specific cell surface proteins for the molecular imaging of the beta cells has not been successful, it remains that such proteins would be useful targets for clinical PET imaging of beta cell mass or function. One possible biomarker that may reflect changes in beta cell function during the development of diabetes is the large neutral amino acid transporter, LAT1 (SLC7A5). LAT1 is a member of the solute carrier (SLC) transporter family of proteins that controls the uptake and efflux of solutes such as metabolites, ions, toxins and drugs. It is a Na + -independent exchanger of amino acids with large neutral side chains, such as leucine, isoleucine, valine, tyrosine, tryptophan and methionine (reviewed in 18). LAT1 is expressed in the brain, testis and placenta, and is highly abundant in the blood-brain barrier 19 , where it mediates the transport of metabolites and drugs into the CNS. Its expression is up-regulated in a variety of cancers, where it is thought to enhance the transport of amino acids required for nutritional support and signaling molecules for proliferation, and a number of PET imaging agents targeting LAT1 have been developed and tested for a range of human cancers [20] [21] [22] [23] . One such tracer, [
18 F]-L-FEHTP, has been shown to specifically target LAT1 in cancer cells 24 ; remarkably, it also showed high uptake in the pancreas in mice, leading us to investigate its use in imaging beta cells.
LAT1 is expressed on the surface of pancreatic beta cells 25 . Recently, alterations in islet LAT1 expression at the level of transcription have been linked to the development of beta cell dysfunction in a mouse model of diabetes in which a loss of regulation of amino acid transport leads to beta cell apoptosis 26 . We therefore used the previously synthesized LAT1-targeted PET tracer, [
18 F]-L-FEHTP, and characterized its potential for the molecular imaging of beta cell function in diabetes.
Materials and methods

Synthesis and Labeling of 18
F-L-FEHTP 18 F-L-FEHTP was prepared by 2-step radiolabeling modeled after similar methods previously described 24, 27 . 18 F-fluoride was produced by 18 O(p,n) 18 F nuclear reaction bombarding enriched 18 O-water in a cyclotron (PETtrace; GE). The fluoride was loaded onto an automated synthesis unit (Tracerlab FX F-N ; GE) where it was trapped on an anion-exchange cartridge (QMA Light; Waters). The activity was eluted with a 1 mL solution of 1:4 water/ACN with Cryptand 222 (15 mg; ABX) and potassium carbonate (5 mg; Aldrich). The activity was dried under a stream of nitrogen with vacuum at 95°C. Acetonitrile (0.5 mL) was added and dried twice to remove residual water azeotropically. A 1 mL solution of ethylene di(p-toluenesulfonate) (10 mg, Aldrich) in acetonitrile was added and the mixture was heated for 6 min at 85°C. The reaction mixture was cooled and the 18 F-labeled product was isolated by semi-preparative HPLC. The collected fraction was diluted in water and loaded onto a C-18 cartridge (Waters). The product was eluted in 2 mL of dimethyl sulfoxide (DMSO) and passed off of the automated synthesis unit into an adjoining hot cell for the second stage of the reaction.
5-Hydroxy-L-tryptophan disodium salt was prepared by combining 5-hydroxy-L-tryptophan (10 mg; Aldrich) with 2 equivalents of sodium methoxide in methanol (Aldrich) at room temperature. The methanol was removed by rotary evaporator (V-10; Biotage) and the salt was brought up in DMSO. The solution was transferred to a reaction vial under nitrogen. An aliquot of the 18 F-labeled tosylate was added to the reaction vial and heated at 105 °C for 15 min. The reaction mixture was diluted with water and purified by semi-preparative HPLC, and the mobile phase from the collected fraction was removed by rotary evaporator.
18 F-L-FEHTP product was dissolved in phosphate buffered saline with 8% ethanol and sterile filtered prior to use. Synthesis of the 18 F-labelled tosylate
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on the automated synthesis unit yielded approximately 30% (decay corrected). The second reaction produced approximately 50% (decay corrected) isolated 18 F-L-FEHTP in final buffered solution. The radiochemical purity of the final product was greater than 98%.
PET imaging and image analysis All mice were treated in accordance with the ethical guidelines set out by the Animal Use Subcommittee of the Canadian Council on Animal Care at Western University (protocol #2012-020). Both wild-type (wt) C57BL/6J male mice and C57BL/6J-Ins2C 56 Y (Akita) male mice were obtained from Jackson Labs at 5 weeks of age, and imaging experiments were conducted at 6-7 weeks of age. For streptozotocin-treated mice, 8 female C57BL/6J mice were obtained from Jackson labs and randomly assigned to control (n = 4) or streptozotocin (STZ) treatment groups (single i.p. injection of 200 mg/kg, n = 4). Seven days post-injection, blood glucose readings were taken after fasting for 4 h using a One Touch Ultra glucometer (Lifescan Inc, Milpitas, CA). Diabetes was determined by glycemia ≥11 mmol/L. Imaging was conducted 8 days post-STZ injection.
All mice were fasted for 4h prior to the imaging session. Akita mice and corresponding controls were anesthetized with 0.5-2% isoflurane by inhalation, administered 6.45-15.8 MBq [ PET image acquisition was conducted as described previously 5 , with a dynamic scan for 1 h and a subsequent static scan for 30 min. Images were reconstructed and standardized uptake values (SUVs) were calculated as described previously 5 , using regions of interest (ROIs) drawn through six image slices corresponding to the areas of the kidneys and pancreas.
Biodistribution
To provide a pharmacokinetic profile of [ 18 F]-L-FEHTP uptake, select organs, as well as urine and blood, were removed and weighed immediately after cessation of the imaging session, and counted in a high-purity Ge gamma counter, as described previously 5, 11 . Data were calculated as % injected dose/g (%ID/g) tissue and all activity was decay-corrected to the time of injection.
Immunofluorescence microscopy and image analysis Immediately after counting, all pancreata from both wt and Akita mice were embedded in frozen tissue embedding gel (OCT, Fisher) for immunofluorescence microscopy analysis of LAT1. Serial sections were cut at 8 μm thickness, and three sections from each pancreas were selected for immunohistochemistry as described previously 5 . Primary antibodies against insulin (polyclonal anti-guinea pig, 1:1000, Bachem, Cat # ab7842) and SLC7A5 (polyclonal anti-rabbit, 1:100, Sigma Chemical, Product# HPA052673) and respective Alexa secondary antibodies (Alexa 597, goat anti-guinea pig and Alexa 488, goat anti-rabbit) were used to visualize insulin and LAT1. Sections were also stained with Hoechst 33342 (Sigma) for nuclei visualization. Two to 10 fields of view per section were acquired at 20× magnification using Nikon NIS Elements v. BR 4.50.00 software and imported into ImageJ (Fiji) v.1.49v for analysis.
For image analysis, one ROI was drawn within each islet, two ROIs were drawn in the non-islet, non-ductal pancreatic areas and two ROIs were drawn in background regions of each field of view using the circle tool in ImageJ with an area of approximately 15000 pixels, as we have done previously [28] [29] [30] . Fluorescence intensities were calculated as corrected total cell fluorescence (CTCF) as follows:
CTCF = Raw Integrated density -(Area selected * mean background fluorescence)
Beta-cell mass and morphometric analysis Immediately following the static imaging session, STZ-treated mice were euthanized by CO 2 , and the dissected pancreata immediately fixed in 4% paraformaldehyde (PFA, Electron Microscopy Sciences, Hatfield, PA) for 24 h. Pancreata were prepared according to Beamish et al. 31 . Seven micron thick cryosections were cut sequentially (Leica CM 1850 cryostat) from at least 3 layers, with an interval between each layer > 150 μm. Immunochemical staining followed Chamson-Reig et al.
32 using a human anti-mouse insulin primary antibody (1/200, Sigma Chemical, St Louis, MO), horse-anti-mouse secondary antibody (Vector Laboratories), and DAB chromagen (Biogenics Laboratories, Fremont, CA) according to manufacturer's instructions. Three sections from different layers of pancreas were immunostained and analyzed. The entire pancreas section was imaged at 2.5X magnification, and insulinpositive cells were imaged at 40X magnification using Northern Eclipse software (v. 6.0, Empix Imaging, Mississauga ON Canada). Pancreas-and insulin-positive areas were measured by tracing using ImageJ v. 1.50b. Beta cell mass was calculated by dividing insulin-positive area by total pancreas area, then multiplying by pancreas weight.
Statistical analyses
For biodistribution data, statistical significance between the wt and Akita organs was determined using one-way ANOVA followed by a Tukey post-hoc test. Differences in % ID/g between corresponding organs in the wt and Akita were compared with an unpaired one tailed Student's t-test. For PET images, differences in SUVs were analysed using an unpaired one-tailed Student's t-test. For microscopy images, differences in fluorescence values were determined using the Mann-Whitney U test. For correlation of SUV and beta cell mass, linear regression analysis was used. All statistical analyses were carried out on GraphPad Prism v. 6.01. Significance was set at p<0.05 for all experiments.
Results
Ex vivo biodistribution of 18 F-L-FEHTP in Akita mice
To determine 18 F-L-FEHTP uptake by various tissues, ex vivo organ biodistribution was assessed in wt mice immediately after PET imaging (Figure 1 ). Uptake in the pancreas was significantly greater (p<0.05) from all other tissues except heart (p = 0.485) and liver (p = 0.2029).
We then compared uptake of 18 F-L-FEHTP in the pancreas of wt and Akita mice, which were previously reported to have higher LAT1 mRNA expression in pancreatic beta cells. There was notable variability in 18 F-L-FEHTP uptake in the pancreata of Akita mice (Figure 2A ). The pancreas of the Akita mice group showed no significant difference in 18 F-L-FEHTP uptake from the wt pancreas ( Figure 2A) . Ex vivo biodistribution of all organs in Akita mice showed no significant differences in 18 F-L-FEHTP uptake except the liver (p = 0.0144) ( Table 1) .
PET imaging: static scan analysis In order to determine if 18 F-L-FEHTP PET could detect changes in pancreatic LAT1 activity due to diabetes, static images were acquired for 30 min 1 h after 18 F-L-FEHTP injections for both wt and Akita mice. The pancreas was clearly visualized with little detectable background uptake ( Figure 2B and Supplementary  Figure 1 ). The SUVs (means ± SEM) calculated from pancreatic ROIs were 1.5 ± 0.04 and 1.3 ± 0.04 for wt and Akita mice, respectively, and these values were not significantly different.
Immunofluorescence microscopy of LAT1 in pancreas tissue To investigate possible changes in LAT1 protein in pancreatic beta cells, immunofluorescence microscopy for LAT1 was conducted on pancreas sections from mice that had been imaged. Figure 3A shows representative immunofluorescence images for LAT1 and insulin in wt and Akita mice. Image analysis showed that there was significantly less LAT1 immunofluorescence in pancreatic islets from Akita mice, as well as in non-islet, non-ductal tissue ( Figure 3B ). Additionally, there were no differences in total cell fluorescence between islets and the rest of the pancreas in both wt and Akita mice. This indicates that, at the protein level, LAT1 expression decreased in both islets and the rest of the pancreas in 6-week-old male Akita mice. Insulin immunofluorescence decreased by 62 ± 3% (p =0.0009) in Akita mice; however, total , n = 6, p = 0.3).
Dynamic scan analysis
Time-activity curves for 18 F-L-FEHTP activity in the kidneys and pancreata of wt and Akita mice are shown in Figure 4 . ROIs were assigned for the first and final frame (corresponding to 5 min and 60 min) around the kidneys and pancreas respectively. These frames were chosen because the tracer distributed to the kidneys initially ( Figure 4B ) and then accumulated in the pancreas ( Figure 4A ). Activity in the Akita group was consistently less than in the wt group for both organs (Figure 4) . In the pancreas, the Akita mice had significantly less 
LAT1 imaging in STZ-treated mice
Imaging data in Akita mice seemed to suggest that the decrease in 18 F-L-FEHTP correlated with a decrease in pancreatic LAT1 overall and was not specific to islets. We then examined 18 F-L-FEHTP uptake in a known model of decreased beta cell mass to test the sensitivity of the tracer. Fasting blood glucose levels from STZ-treated mice were significantly higher than control (non-diabetic) animals (17.8 ± 3.7 mM vs 7.6 ± 0.2 mM, n = 4, p = 0.0161), which was commensurate with a 62% decrease in β-cell mass in STZ vs control mice (0.26 ± 0.04 mg vs 0.68 ± 0.08 mg, p < 0.0005). However, pancreatic uptake of 18 F-L-FEHTP as assessed by both static (0.9 ± 1.7 vs 0.8 ± 0.1, p = 0.3) and dynamic PET scans ( Figure 5 ) was not different between the two groups, and there was no significant correlation (r = 0.2416) between pancreatic static SUVs and beta cell mass ( Figure 6 ). Raw BCM data for Figure 6 . Uptake is given as SUVs from static scans from both control and STZ-treated mice.
Discussion
The PET tracer, 18 F-L-FEHTP, is known to specifically target the amino acid transporter LAT1. Since the expression of the mRNA for LAT1 shows dramatic changes in pancreatic islets during the development of diabetes in the Akita mouse model 26 , we used 18 F-L-FEHTP in an effort to track these changes in vivo, and hypothesized that 18 F-L-FEHTP uptake could be a surrogate measure for beta cell function. We also tested the hypothesis that 18 F-L-FEHTP uptake could be an in vivo measure of beta cell mass by examining uptake in STZ-treated mice, a model of beta cell depletion. Interestingly, PET images of 18 F-L-FEHTP uptake showed a strong signal in the pancreas, with minimal background uptake in the kidneys or liver. In male Akita mice, time-activity curves showed significantly reduced uptake of 18 F-L-FEHTP, and immunofluorescence microscopy revealed a significant reduction in LAT1 in islets and the rest of the pancreas. However, there was no correlation of 18 F-L-FEHTP uptake with beta cell function, nor with beta cell mass in STZ-treated mice. We showed that LAT1 was expressed throughout the pancreas, which may lead to challenges in detecting changes in LAT1 only in the islets, as they comprise 1% of total pancreatic volume. , or a racemic mixture of fluoropropyl tryptophan 22 , as well as the fluoro-ethoxy analogue used in the present study, 18 F-L-FEHTP 24 . We chose 18 F-L-FEHTP as a PET tracer that targets LAT1 since the biodistribution data in mice indicated the highest uptake in non-tumor tissue was in the pancreas, and the PET images in this study did not show appreciable background signal. Indeed, our own images show accumulation of the PET signal specifically in the area of the pancreas, with little background uptake in the kidneys or liver (although, uptake in the intestine and spleen cannot be ruled out). As well, uptake, efflux and metabolism of 18 F-L-FEHTP have been very well The C96Y mutation in the mouse Ins2 gene that characterizes the Akita mouse has been shown to induce beta cell apoptosis by failing to exit the ER and inducing ER stress 33 , and this same mutation has been implicated in the development of permanent neonatal diabetes in humans 34 . As proposed by Krokowski et al.
26
, prolonged ER stress caused by induction of protein synthesis in beta cells involves increased amino acid flux through a network of transporters that leads to increased tRNA charging with LAT1 substrates such as leucine and tryptophan. In particular, LAT1 mRNA levels were significantly up-regulated during translational recovery in islets from 6-week-old male Akita mice, leading to the hypothesis that changes in LAT1 in islets could serve as a diagnostic biomarker for the early development of diabetes. Therefore, we reasoned that 18 F-L-FEHTP would be a surrogate marker for the decline in beta cell function resulting from prolonged ER stress. In the present study, we first conducted PET imaging studies using the Akita mouse model. However, our PET imaging results suggest that 18 F-L-FEHTP uptake was decreased in Akita mice, and immunofluorescence microscopy suggests that islet LAT1 also decreased.
It is possible that the decrease 18 F-L-FEHTP uptake may be a function of a decline in beta cell mass. However, our results show no decrease in islet area, although there is a significant decrease in insulin immunofluorescence within islets. There is some conflicting evidence on changes in beta cell mass in Akita mice: in 8-week-old male mice, there is roughly a 50% decrease 35 , while in 8-week-old female mice, there is no change, despite the sharp reduction in islet insulin content 36 . Our results indicate that, in 6-week-old Akita male mice in our facility, ongoing ER stress is diminishing insulin synthesis, but has not yet affected islet size. Additionally, our analysis shows that there is no correlation between blood glucose levels and 18 F-L-FEHTP uptake, indicating that imaging changes in LAT1 is not a surrogate measure for beta cell function.
Since islet area did not change in our Akita mice, we tested 18 F-L-FEHTP uptake in a model of diabetes in which a dramatic decrease in beta cell mass is well documented. When treated with a single injection of 200 mg/kg STZ, female C57BL/6 mice showed a > 60% decrease in beta cell mass. However, there was no corresponding decrease in 18 F-L-FEHTP uptake as assessed by either dynamic or static SUV analysis. Therefore, despite the loss of beta cells and associated LAT1 expression, no change in 18 F-L-FEHTP uptake could be detected, leading us to conclude that 18 F-L-FEHTP uptake is not a surrogate measure of changes in beta cell mass during the progression of diabetes.
Is
18 F-L-FEHTP uptake a function of LAT1 expression? Our results show that both 18 F-L-FEHTP uptake and LAT1 immunofluorescence are decreased in pancreatic tissue from Akita mice, so it appears that imaging with 18 F-L-FEHTP can report LAT1 activity. However, LAT1 mRNA levels are increased in Akita islets 26 , indicating that there may be an additional level of control in the expression of LAT1 in ER stress-dependent diabetes. There is evidence that LAT1 and other transporters are regulated differentially at the transcriptional and post-translational levels. Glucose deprivation increases LAT1 mRNA and protein expression and [
3 H]Leu transport activity in retinal endothelial cells 37 . Interestingly, high glucose levels did not change LAT1 mRNA levels, indicating that hyperglycemia may regulate LAT1 at a post-translational level. Another study suggests a mechanism for post-translational regulation, as LAT1 localization to the plasma membrane is impaired by hyperoxia in alveolar epithelial cells 38 , indicating that stress conditions can induce improper LAT1 trafficking, resulting in loss of transporter activity. Finally, another amino acid transporter, system A/SNAT2 (SLC38A2), is regulated differentially at the transcriptional and post-translational levels. Amino acid starvation and hypertonicity increase SNAT2 mRNA; however, stress conditions promote the proteasome-dependent degradation of SNAT2 39,40 . It is possible that LAT1 in beta cells could be differentially regulated at the transcriptional and post-translational level in a similar manner, with nutrient availability and/or signaling determining the trafficking or degradation of LAT1 protein.
Since LAT1 is expressed in both the endocrine and exocrine compartments of the pancreas, the signal is likely due to uptake of 18 F-L-FEHTP in both compartments. It was tempting for us to test the sensitivity of 18 F-L-FEHTP in a model of pancreatic cancer. However, although the expression of many amino acid transporters do change in caerulein-induced pancreatitis, slc7A5/ LAT1 expression/immunoreactivity does not 41, 42 . So although 18 F-L-FEHTP is taken up and retained in certain types of cancers 24 , it is not an appropriate imaging probe for the detection of pancreatic cancer.
In order to differentiate islet uptake from acinar uptake, it has been estimated that the signal of any imaging probe must be 1000-fold higher in beta cells than in the surrounding acinar/ductal cells 43 , due to the fact that beta cells comprise <1% of pancreatic volume. Our study clearly demonstrates that this is not the case for LAT1. The data for other presumptive beta cell imaging targets, such as VMAT2, GLP-1R, and the 5-HT metabolic pathway in human islets, are limited. A recent study showed that mRNA levels of VMAT2 in human pancreas were 500-fold higher in islets compared with exocrine cells 44 ; however, there was still significant uptake of [
18 F]FP-(+)-DTBZ in patients with T1D and no residual beta cell function. Using autoradiography, it has been reported that there is about 2X as many GLP-1 receptors in human islets than in acinar cells 45 . We have shown the presence of GLP-1R in glucagon-and amylase-positive cells 11 and there is evidence for lowlevel expression of GLP-1R in exocrine pancreas. Finally, uptake of [ 11 C]-hydroxytryptophan, postulated to be a surrogate measure of beta cell mass by targeting the serotonergic pathway, is 14 times higher in human islets than in exocrine cells 46 , and there is a small but significant decrease in uptake in patients with T1D. Therefore, there is still some promise of a non-invasive method to image changes in beta cell function and mass during the progression of diabetes. Further characterization of 18 F-L-FEHTP uptake and retention in human islets, and not in rodent-derived cell lines or islets, may be required.
Conclusions
In the present study, we have shown specific accumulation of 18 F-L-FEHTP in the pancreata of mice, with minimal background signal from the kidneys, liver or intestine. Such clear visualization of the pancreas using a targeted PET agent in mice has not previously been achieved. The PET signal represents the total integrated tracer uptake in the pancreas, and we could not detect changes in beta cell function or mass using our mouse models of Type 1 diabetes. 1.
In the introduction, the authors mention another study that they published where PET was used to successfully image changes in beta cell mass prior to fasting hyperglycemia. I think it's important, for the context and rationale of this work, to explain why a different tracer was needed for this work since as written it appears they already have a good tracer (although reading the reference would make it clear that they actually imaged a reporter gene).
In the introduction, the sentence that discusses VMAT2 expression in other tissues is incomplete. Many PET tracers that image receptor expression are expressed in a variety of tissues and this does prevent their use. A bit more information should be added at the end of the sentence to help the reader understand why VMAT2 expression in other tissues resulted in such poor PET images.
The second image in Figure 2B has the arrow pointing into a location without any tracer uptake. I don't think that is intentional and it is close to an area with high uptake. Although slight, the arrow should be moved a bit to clearly point out the pancreas in that specific image. In addition, the figure would be generally improved by labelling all organs that demonstrate high tracer uptake in the PET images.
Would it have been reasonable to perform statistical analysis to determine if there is a potential outlier in the Akita mouse data (with very high pancreatic uptake) as shown in Figure 2A ?
In paragraph 1 of the discussion, use of the word "amazingly" seems inappropriate in the paper. It is established that LAT1 is highly expressed in the pancreas and high uptake was previously reported for this tracer by Kramer , (2012) so I wasn't really "amazed" by the high uptake. The et al uptake in the pancreas is indeed impressive however.
In agreement with Dr. Virostko, I am a bit confused why there are dramatic changes in the % injected dose/g values measured in pancreas vs the kidney from the biodistribution data but much smaller relative changes in the SUV values obtained from the PET data. Can the authors explain this as I could be missing something? At least a comment in the text would be valuable.
Is there really no significant differences in uptake between the pancreas and blood shown in Figure  1? 1.
3.
It is interesting that the kidney of Akita mice also exhibits a statistically significant decline in tracer uptake. Is there known LAT expression in the kidney that would explain this finding?
The authors state that: 'Such clear visualization of the pancreas using a targeted PET agent has not previously been achieved.' Does the level of pancreatic uptake exceed that previously achieved with C11-acetate, another tracer with high pancreas uptake? This is an excellent question and one which everyone who characterizes a new PET tracer should think about. First, one difference between calculation of biodistribution and SUV data is that SUV is normalized to body weight, while biodistribution is normalized to organ weight. Second, SUVs calculated in the context of a dynamic scan gives an idea of tracer flux through the tissue, while bioD is a measure of the activity in each organ in the absence of blood circulation. These differences may account for the mismatch in the final time point of the TAC and the biodistribution results. These differences may also explain why liver uptake appears high in the bioD, but the liver signal cannot be discerned in the PET images.
The supplementary video shows that there was uptake in other organs (which do not appear in the images shown in figure 2). We agree that accumulation of activity in the spleen cannot be ruled out, and have inserted this comment in the Discussion (paragraph 2).
We thank Dr. Virotsko for alerting us to this error, and we have corrected the section under Dynamic Scan Analysis.Literature evidence (Fotiadis, Reference #18) does not et al. support LAT1 renal expression.
We have inserted the words "in mice" to reflect the fact that we are comparing our results to probes that target specific biomarkers (GLP-1R, VMAT2) in mouse pancreas. The key word in our statement is "targeted". 11C-acetate does not target a specific mechanism, as its means of uptake and retention are not known. Studies of 11C-acetate have been done exclusively on humans and it is difficult to compare SUVs of 18F-FEHTP in mice and 11C-acetate in humans. The mean SUV of 11C-acetate activity in normal human pancreas is reported at 11.9±4. We thank Dr. Virotsko for this suggestion and have connected the points in the TAC in 5. We thank Dr. Virotsko for this suggestion and have connected the points in the TAC in Figure 5 .
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